__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Efficacy of LUCENTIS in different ophthalmic indications.

Indications¹

LUCENTIS 0.5 mg is indicated in adults for:

• The treatment of neovascular (wet) age-related macular degeneration (AMD)
• The treatment of visual impairment due to diabetic macular oedema (DMO)
• The treatment of proliferative diabetic retinopathy (PDR)
• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
• The treatment of visual impairment due to choroidal neovascularisation (CNV).

LUCENTIS 0.2 mg is indicated in preterm infants for:

• The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

AMD, age-related macular degeneration; DMO, diabetic macular oedema; ROP, retinopathy of prematurity.

Reference

1. LUCENTIS^® (ranibizumab) Summary of Product Characteristics, July 2020.